ERα-positive breast cancers typically respond well to therapy that attenuates ERα signaling, either by blocking the production of estrogens via aromatase inhibitors, or antagonizing the activity of estrogens through competitive binding of ER antagonists such as tamoxifen (Puhalla et al., 2012). This evidence concerns the gene CYP19A1 and breast cancer.